Literature DB >> 20044254

Side chain SAR of bicyclic beta-lactamase inhibitors (BLIs). 1. Discovery of a class C BLI for combination with imipinem.

Timothy A Blizzard1, Helen Chen, Seongkon Kim, Jane Wu, Katherine Young, Young-Whan Park, Amy Ogawa, Susan Raghoobar, Ronald E Painter, Nichelle Hairston, Sang Ho Lee, Andrew Misura, Tom Felcetto, Paula Fitzgerald, Nandini Sharma, Jun Lu, Sookhee Ha, Emily Hickey, Jeff Hermes, Milton L Hammond.   

Abstract

Bridged monobactam beta-lactamase inhibitors were prepared and evaluated as potential partners for combination with imipenem to overcome class C beta-lactamase mediated resistance. The (S)-azepine analog 2 was found to be effective in both in vitro and in vivo assays and was selected for preclinical development. Copyright (c) 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 20044254     DOI： 10.1016/j.bmcl.2009.12.069

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN： 0960-894X            Impact factor:   2.823


  9 in total

1.  An Automated Miniaturized Method to Perform and Analyze Antimicrobial Drug Synergy Assays.

Authors:  Peter Chase; Imarhia Enogieru; Franck Madoux; Eric Bishop; Jacob Beer; Louis Scampavia; Timothy Spicer
Journal:  Assay Drug Dev Technol       Date:  2015-12-15       Impact factor: 1.738

Review 2.  New promising β-lactamase inhibitors for clinical use.

Authors:  I Olsen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-04-12       Impact factor: 3.267

3.  Exploring sequence requirements for C₃/C₄ carboxylate recognition in the Pseudomonas aeruginosa cephalosporinase: Insights into plasticity of the AmpC β-lactamase.

Authors:  Sarah M Drawz; Magdalena Taracila; Emilia Caselli; Fabio Prati; Robert A Bonomo
Journal:  Protein Sci       Date:  2011-05-03       Impact factor: 6.725

4.  Selection of AmpC β-Lactamase Variants and Metallo-β-Lactamases Leading to Ceftolozane/Tazobactam and Ceftazidime/Avibactam Resistance during Treatment of MDR/XDR Pseudomonas aeruginosa Infections.

Authors:  Alba Ruedas-López; Isaac Alonso-García; Cristina Lasarte-Monterrubio; Paula Guijarro-Sánchez; Eva Gato; Juan Carlos Vázquez-Ucha; Juan Andrés Vallejo; Pablo Arturo Fraile-Ribot; Begoña Fernández-Pérez; David Velasco; José María Gutiérrez-Urbón; Marina Oviaño; Alejandro Beceiro; Concepción González-Bello; Antonio Oliver; Jorge Arca-Suárez; Germán Bou
Journal:  Antimicrob Agents Chemother       Date:  2021-12-20       Impact factor: 5.938

Review 5.  Class C β-Lactamases: Molecular Characteristics.

Authors:  Alain Philippon; Guillaume Arlet; Roger Labia; Bogdan I Iorga
Journal:  Clin Microbiol Rev       Date:  2022-04-18       Impact factor: 50.129

Review 6.  New β-Lactamase Inhibitors in the Clinic.

Authors:  Krisztina M Papp-Wallace; Robert A Bonomo
Journal:  Infect Dis Clin North Am       Date:  2016-06       Impact factor: 5.982

7.  Structure of the extended-spectrum class C β-lactamase ADC-1 from Acinetobacter baumannii.

Authors:  Monolekha Bhattacharya; Marta Toth; Nuno Tiago Antunes; Clyde A Smith; Sergei B Vakulenko
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2014-02-22

8.  Mutations in β-Lactamase AmpC Increase Resistance of Pseudomonas aeruginosa Isolates to Antipseudomonal Cephalosporins.

Authors:  M Berrazeg; K Jeannot; Véronique Yvette Ntsogo Enguéné; I Broutin; S Loeffert; D Fournier; P Plésiat
Journal:  Antimicrob Agents Chemother       Date:  2015-07-27       Impact factor: 5.191

9.  Flexibility Correlation between Active Site Regions Is Conserved across Four AmpC β-Lactamase Enzymes.

Authors:  Jenna R Brown; Dennis R Livesay
Journal:  PLoS One       Date:  2015-05-27       Impact factor: 3.240
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.